Pharma Equity Group A/S (OCSE:PEG) Interest Expense : kr-2.52 Mil (TTM As of Mar. 2024)

View and export this data going back to 2003. Start your Free Trial

What is Pharma Equity Group A/S Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Pharma Equity Group A/S's interest expense for the three months ended in Mar. 2024 was kr -0.96 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2024 was kr-2.52 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Pharma Equity Group A/S's Operating Income for the three months ended in Mar. 2024 was kr -6.83 Mil. Pharma Equity Group A/S's Interest Expense for the three months ended in Mar. 2024 was kr -0.96 Mil. Pharma Equity Group A/S did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Pharma Equity Group A/S Interest Expense Historical Data

The historical data trend for Pharma Equity Group A/S's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharma Equity Group A/S Interest Expense Chart

Pharma Equity Group A/S Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-0.03

-0.27

-0.67

-0.02

-1.56

Pharma Equity Group A/S Quarterly Data
	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Interest Expense	Get a 7-Day Free Trial															-	-0.45	-0.43	-0.68	-0.96

Pharma Equity Group A/S Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-2.52 Mil.

Pharma Equity Group A/S (OCSE:PEG) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Pharma Equity Group A/S's Interest Expense for the three months ended in Mar. 2024 was kr-0.96 Mil. Its Operating Income for the three months ended in Mar. 2024 was kr-6.83 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2024 was kr16.02 Mil.

Pharma Equity Group A/S's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as

Pharma Equity Group A/S did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Pharma Equity Group A/S (OCSE:PEG) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharma Equity Group A/S (OCSE:PEG) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

Slotsmarken 18, 2.th., Horsholm, DNK, DK-2970

Website

https://www.pharmaequitygroup.com

Pharma Equity Group A/S is an investment company specializing in the life science industry. The group is focused on an early investment in various life science companies that develops technologies and therapies that have the potential to improve human health and quality of life. The group specializes in early-stage investments in biotechnology, that are developing novel therapies for unmet medical needs. Its portfolio consists of companies dedicated to developing novel, effective treatments for diseases with patient and social impact for which current therapy is lacking or in need of improvement.